RxDoctor Payments Data

Pedro Medina

Family · El Paso, TXNPI 1366915613

Payments from drug & device makers

$6,798in general payments, 2019–2025

Across 142 payments — averaging $47.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Inari Medical, Inc.$1K
  • Medtronic$1K
  • Johnson & Johnson$560
  • Abbott$474
  • Biotronik Inc.$175
  • plus $958 from 13 others

What the payments were for

  • Speaking & faculty fees$4707%
  • Travel & lodging$1,32820%
  • Food & beverage$4,81071%
  • Education$1893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,798 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$13,191
Medicare patients
58
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$73,800
XareltoRivaroxaban26$38,779
EntrestoSacubitril/Valsartan17$19,457
Ranolazine ErRanolazine30$2,856
ClopidogrelClopidogrel Bisulfate97$912
Atorvastatin Calcium40$477
Carvedilol43$460
Lisinopril59$310
Metoprolol Succinate24$303
Losartan Potassium35$291
Spironolactone25$242
Nitroglycerin19$182
Rosuvastatin Calcium13$165
Gabapentin18$150
Metoprolol Tartrate31$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$153$73,80056 claims
Johnson & JohnsonXarelto$560$38,77926 claims
NovartisEntresto$124$19,45717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →